Xencor Reports Second Quarter 2021 Financial Results August 4, 2021 -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--(BUSINESS WIRE)--Aug. 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights. "Xenco ...

Xencor, Inc. (NASDAQ:XNCR) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and Investor Relations Bassil Dahiyat - President and Chief Executive Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Allen Yang - Chief Medical Officer Conference Call Participants Ted Tenthoff - Piper Sandler Jonathan Chang - SVB Leerink Peter Lawson - Barclays Arlinda Lee - Canaccord Kaveri Pohlman - BTIG Xinyue Lu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-162250 ...

| --- | --- | --- | --- | --- | |-------|----------------------------------|-------|-------|-------| | | | | | | | | Proteins by Design | ® | | | | | Antibody & Cytokine Therapeutics | | | | Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's deve ...

Xencor, Inc. (NASDAQ:XNCR) Q1 2021 Results Conference Call May 5, 2021 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Sandler Mara Goldstein - Mizuho Securities Peter Lawson - Barclays Li Wang Watsek - Cantor Etzer Darout - Guggenheim Tom Shrader - BTIG Zhiqiang Sh ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-16225 ...

Xencor Inc (NASDAQ:XNCR) Q4 2020 Earnings Conference Call February 23, 2021 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Sandler Mara Goldstein - Mizuho Securities Gregory Renza - RBC Capital Markets Alethia Young - Cantor Fitzgerald Jonathan Chang - SVB Leerink ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or Or ...

Financial Data and Key Metrics Changes - As of September 30, 2020, cash, cash equivalents, and marketable securities totaled $582.9 million, down from $601.3 million at December 31, 2019, reflecting cash used for operating activities [31] - Total revenue for Q3 2020 was $35.4 million, compared to $21.8 million for the same period in 2019, driven by milestone revenue from MorphoSys and licensing revenue from Omeros [32] - Total revenue for the nine months ended September 30, 2020, was $80.8 million, down from $153.2 million for the same period in 2019, primarily due to higher collaboration licensing revenue in 2019 [33] - Research and development expenditures for Q3 2020 were $44.5 million, up from $29.8 million in Q3 2019, reflecting increased spending on clinical programs [34] - Net loss for Q3 2020 was $12.6 million, or $0.22 per share, compared to a net loss of $10.2 million, or $0.18 per share, for the same period in 2019 [37] - For the nine months ended September 30, 2020, net loss was $55.6 million, or $0.97 per share, compared to net income of $53.8 million, or $0.92 per share, for the same period in 2019 [38] Business Line Data and Key Metrics Changes - The company is currently running six Phase I clinical studies evaluating XmAb bispecific antibodies, with a focus on oncology treatments [9] - The autoimmune IL-2 Fc program, XmAb27564, is on track for a Phase I study initiation in early 2021 [12][23] - The company has 12 ongoing partnerships for XmAb technology, resulting in two marketed products: Alexion's ULTOMIRIS and MorphoSys' Monjuvi [26] Market Data and Key Metrics Changes - The COVID-19 pandemic did not significantly disrupt patient enrollment in ongoing clinical studies, although there were critical shortages of materials affecting manufacturing processes [11] - Partnerships with companies like Genentech and Omeros continue to generate revenue without significant COVID-19 impacts [24] Company Strategy and Development Direction - The company is focusing on expanding its XmAb bispecific platform to create antibodies that bind multiple targets and engineer cytokines optimized for therapeutic use [9] - Partnerships are a core part of the business model, generating payments from licensing XmAb technologies and royalties from approved products [24] - The company is exploring opportunities to develop vibecotamab in patients with lower baseline leukemic disease burden [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing clinical programs and the potential for advancing multiple assets based on emerging proof-of-concept data [89] - The company expects to have sufficient cash to fund R&D programs and operations into 2024, projecting to end 2020 with between $525 million and $575 million in cash [39] Other Important Information - The company is maintaining remote work requirements for non-laboratory employees while ensuring on-site safety measures for those working in labs [12] - The company is developing a suite of cytokines engineered with XmAb bispecific Fc domains to improve their properties and drug-like characteristics [21] Q&A Session Summary Question: Next steps for CD123 for AML - Management indicated that they have restrictions due to the partnership with Novartis but noted that they observed more activity in patients with lower disease burdens [41][44] Question: Bar for AML in this population - Management stated that the populations possible with the agent vary, and they have good ideas about the bar without disclosing specifics [46] Question: Confidence in tolerability of 20717 - Management discussed the design of the molecule, which requires cooperative binding for strong binding, and noted that the tolerability profile is encouraging [50][54] Question: Planned studies for plamotamab - Management confirmed that Phase II studies are planned for relapsed refractory DLBCL, with more details to come [58] Question: Differences in patient characteristics for vibecotamab - Management indicated that there have not been significant changes to inclusion/exclusion criteria, so no major shifts in demographics are expected [72]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-1 ...